Skip to Main Content

Thomas Carpenter, MD

Professor of Pediatrics (Endocrinology) and of Orthopaedics and Rehabilitation and Clinical Professor of Nursing; Director, Yale Center for X-Linked Hypophosphatemia; Medical Director, Hospital Research Unit

Research Summary

Dr. Thomas Carpenter investigates disorders of mineral metabolism in children, including calcium, phosphorus, and Vitamin D (nutritional rickets). Dr. Carpenter is director of the Yale Center for X-Linked Hypophosphatemia (YC-XLH). He also co-chairs a committee which functions in concert with the Human Investigation Committee and the Yale Center for Clinical Investigation to insure the highest quality approach to clinical research and optimum measures of safety in pediatric research.

Specialized Terms: Regulation of phosphate homeostasis and Vitamin D metabolism; Vitamin and mineral nutrition; Bone cell biology; Assessment of bone density in children; Ethical issues in pediatric research

Extensive Research Description

  • Novel therapy of X-linked hypophosphatemia
  • Pathophysiology of X-linked hypophosphatemia
  • Vitamin D response to supplementation in infants and children

Coauthors

Research Interests

Endocrinology; Hypophosphatemia, Familial; Musculoskeletal Diseases; Orthopedics; Pediatrics; Vitamin D; Bone Density

Selected Publications

  • OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 StudyCarpenter T, Cimms T, Cimms T, Hetzer J, Hetzer J, Insogna K, Kumar R, Kumar R, Merritt II J, Merritt II J, Miller P, Miller P, Peacock M, Peacock M, Rauch F, Rauch F, Stanciu I, Stanciu I, Weber T, Weber T, Jan De Beur S, Jan De Beur S. OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study Journal Of The Endocrine Society 2022, 6: a191-a191. PMCID: PMC9624705, DOI: 10.1210/jendso/bvac150.394.
  • OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring ProgramCarpenter T, Cassinelli H, Glorieux F, Hetzer J, Merritt II J, Moreira C, Portale A, Ward L, Woo C, Imel E. OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program Journal Of The Endocrine Society 2022, 6: a191-a192. PMCID: PMC9624613, DOI: 10.1210/jendso/bvac150.395.
  • Response of enthesopathy in ENPP1 deficiency to enzyme replacement therapy in murine models and enthesopathy comorbidities and quality of life in ENPP1‐deficient adultsAnsh A, Nester C, O'Brien C, Stabach P, Murtada S, Lester E, Khursigara G, Molloy L, Carpenter T, Ferreira C, Braddock D. Response of enthesopathy in ENPP1 deficiency to enzyme replacement therapy in murine models and enthesopathy comorbidities and quality of life in ENPP1‐deficient adults The FASEB Journal 2022, 36 DOI: 10.1096/fasebj.2022.36.s1.r5311.
  • Systematic characterization of enzyme activity on ENPP1 deficiency disease phenotypeAnsh A, Stabach P, Carpenter T, Ferreira C, Braddock D. Systematic characterization of enzyme activity on ENPP1 deficiency disease phenotype The FASEB Journal 2022, 36 DOI: 10.1096/fasebj.2022.36.s1.r5223.
  • Cover, Volume 43, Issue 2Sarafrazi S, Daugherty S, Miller N, Boada P, Carpenter T, Chunn L, Dill K, Econs M, Eisenbeis S, Imel E, Johnson B, Kiel M, Krolczyk S, Ramesan P, Truty R, Sabbagh Y. Cover, Volume 43, Issue 2 Human Mutation 2022, 43: i-i. DOI: 10.1002/humu.24334.
  • Growth curves for children with X-linked hypophosphatemiaMao M, Carpenter T, Whyte M, Skrinar A, Chen C, Martin J, Rogol A. Growth curves for children with X-linked hypophosphatemia 2021 DOI: 10.1530/ey.18.5.5.
  • Hypercalcaemic and Hypocalcaemic Syndromes in ChildrenArdeshirpour L, Carpenter T, Robinson C. Hypercalcaemic and Hypocalcaemic Syndromes in Children 2021, 707-726. DOI: 10.1093/med/9780198870197.003.0087.
  • Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked HypophosphatemiaSimpson C, Simpson C, Santoro A, Santoro A, Carpenter T, Insogna K. Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia Journal Of The Endocrine Society 2021, 5: a27-a27. PMCID: PMC8089365, DOI: 10.1210/jendso/bvab048.052.
  • Burosumab Provides Sustained Improvement in Phosphorus Homeostasis and Heals Rickets in Children Aged 1 to 4 Years With X-Linked Hypophosphatemia (XLH)Gottesman G, Imel E, Carpenter T, Chen A, Skrinar A, Roberts M, Whyte M. Burosumab Provides Sustained Improvement in Phosphorus Homeostasis and Heals Rickets in Children Aged 1 to 4 Years With X-Linked Hypophosphatemia (XLH) Journal Of The Endocrine Society 2021, 5: a251-a251. DOI: 10.1210/jendso/bvab048.511.
  • eP202 A comprehensive locus specific database of PHEX gene variants associated with X-linked hypophosphatemia vastly increases the number of known variantsMiller N, Daugherty S, Sarafrazi S, Boada P, Carpenter T, Chunn L, Econs M, Eisenbeis S, Imel E, Johnson B, Kiel M, Krolczyk S, Ramesan P, Truty R, Sabbagh Y. eP202 A comprehensive locus specific database of PHEX gene variants associated with X-linked hypophosphatemia vastly increases the number of known variants Molecular Genetics And Metabolism 2021, 132: s133. DOI: 10.1016/s1096-7192(21)00287-0.
  • Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone healthHM B, K S, WL R, J R, K N, C R, TO C, EJ C, NS K. Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health 2020 DOI: 10.1530/ey.17.9.16.
  • Enpp1 enzyme replacement restores bone mass in murine model of Enpp1 associated osteoporosisBraddock D, Kavanagh D, Oheim R, Zimmerman K, Kroge S, Stabach P, Tommasini S, Levine M, Carpenter T, Horowitz M. Enpp1 enzyme replacement restores bone mass in murine model of Enpp1 associated osteoporosis Bone Reports 2020, 13: 100623. DOI: 10.1016/j.bonr.2020.100623.
  • ENPP1 regulates bone mass via an unidentified catalytically independent mechanismBraddock D, Zimmerman K, Oheim R, Kroge S, Stabach P, Kavanagh D, Tommasini S, Carpenter T. ENPP1 regulates bone mass via an unidentified catalytically independent mechanism Bone Reports 2020, 13: 100692. DOI: 10.1016/j.bonr.2020.100692.
  • OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 TrialPerwad F, Perwad F, Portale A, Portale A, Carpenter T, Briot K, Briot K, Imel E, Imel E, Kamenicky P, Kamenicky P, Weber T, Weber T, Pitukcheewanont P, Pitukcheewanont P, Cheong H, Cheong H, De Beur S, De Beur S, Imanishi Y, Imanishi Y, Ito N, Ito N, Lachmann R, Lachmann R, Tanaka H, Tanaka H, Zhang L, Zhang L, Skrinar A, Skrinar A, Rees L, Rees L, Insogna K. OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial Journal Of The Endocrine Society 2020, 4: or29-01. PMCID: PMC7209551, DOI: 10.1210/jendso/bvaa046.147.
  • SAT-065 A Novel De Novo GATA3 Gene Mutation in an Adolescent with HDR SyndromeCruz-Aviles L, Bale A, Carpenter T. SAT-065 A Novel De Novo GATA3 Gene Mutation in an Adolescent with HDR Syndrome Journal Of The Endocrine Society 2020, 4: sat-065. PMCID: PMC7208832, DOI: 10.1210/jendso/bvaa046.1845.
  • SUN-LB19 Novel Homozygous Mutation in BMP1 Causing Osteogenesis ImperfectaChoksi I, Carpenter T, Robinson C. SUN-LB19 Novel Homozygous Mutation in BMP1 Causing Osteogenesis Imperfecta Journal Of The Endocrine Society 2020, 4: sun-lb19. PMCID: PMC7209160, DOI: 10.1210/jendso/bvaa046.2020.
  • OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia SyndromeCarpenter T, Miller P, Miller P, Weber T, Weber T, Peacock M, Peacock M, Insogna K, Kumar R, Kumar R, Luca D, Luca D, Cimms T, Cimms T, Roberts M, Roberts M, de Beur S, de Beur S. OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome Journal Of The Endocrine Society 2020, 4: or29-06. PMCID: PMC7208350, DOI: 10.1210/jendso/bvaa046.403.
  • X-linked Hypophosphatemia (XLH): Burosumab Significantly Improved Rickets and Standing Height Z-Score Compared with Conventional Therapy in Children with XLHHart M, Olear E, Chen A, Couto I, Imel E, Carpenter T, Dahir K, Black M. X-linked Hypophosphatemia (XLH): Burosumab Significantly Improved Rickets and Standing Height Z-Score Compared with Conventional Therapy in Children with XLH Journal Of Pediatric Nursing 2020, 52: 111. DOI: 10.1016/j.pedn.2020.02.025.
  • Chapter 20 Phosphorus homeostasis and related disordersCarpenter T, Bergwitz C, Insogna K. Chapter 20 Phosphorus homeostasis and related disorders 2020, 469-507. DOI: 10.1016/b978-0-12-814841-9.00020-8.
  • Missense mutations in ENPP1 result in osteoporosis in patients and is recapitulated in the ENPP1 loss of function murine modelBraddock D, Oheim R, Zimmerman K, Kavanagh D, Horowitz M, Carpenter T. Missense mutations in ENPP1 result in osteoporosis in patients and is recapitulated in the ENPP1 loss of function murine model Bone Abstracts 2019 DOI: 10.1530/boneabs.7.p64.
  • Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemiaHogler W, Carpenter T, Imel E, Portale A, Boot A, Linglart A, Padidela R, Hoff W, Mao M, Skrinar A, Martin J, Whyte M. Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia Bone Abstracts 2019 DOI: 10.1530/boneabs.7.oc15.
  • Growth curves for children with X-linked hypophosphatemiaMao M, Carpenter T, Whyte M, Skrinar A, Chen C, Martin J, Rogol A. Growth curves for children with X-linked hypophosphatemia Bone Abstracts 2019 DOI: 10.1530/boneabs.7.oc17.
  • 011–X-Linked Hypophosphatemia (XLH): New Knowledge for Nurses Regarding Genetics, Pathophysiology and Clinical PresentationCouto I, Hart M, Olear E, Imel E, Carpenter T. 011–X-Linked Hypophosphatemia (XLH): New Knowledge for Nurses Regarding Genetics, Pathophysiology and Clinical Presentation Journal Of Pediatric Nursing 2019, 46: 131. DOI: 10.1016/j.pedn.2019.02.018.
  • OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia SyndromeJan De Beur S, Jan De Beur S, Miller P, Miller P, Weber T, Weber T, Peacock M, Peacock M, Insogna K, Kumar R, Kumar R, Luca D, Luca D, Theodore-Oklota C, Theodore-Oklota C, Lampl K, Lampl K, San Martin J, San Martin J, Carpenter T. OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome Journal Of The Endocrine Society 2019, 3: or13-1. PMCID: PMC6554835, DOI: 10.1210/js.2019-or13-1.
  • OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled TrialsWolf M, Rubin J, Achebe M, Econs M, Peacock M, Imel E, Thomsen L, Carpenter T, Weber T, Zoller H. OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials Journal Of The Endocrine Society 2019, 3: or13-3. PMCID: PMC6554827, DOI: 10.1210/js.2019-or13-3.
  • Burosumab Therapy in Children with X-Linked HypophosphatemiaTO C, MP W, EA I, AM B, W H, A L, R P, W V, M M, CY C, A S, E K, J S, AA P. Burosumab Therapy in Children with X-Linked Hypophosphatemia 2018 DOI: 10.1530/ey.15.5.1.
  • A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH)Kamenicky P, Kamenicky P, Lachmann R, Lachmann R, Carpenter T, Cohen-Solal M, Cohen-Solal M, Eastell R, Eastell R, Brandi M, Brandi M, Crowley R, Crowley R, Ralston S, Ralston S, Javaid M, Javaid M, Keen R, Keen R, Briot K, Briot K, Il C, Il C, Imanishi Y, Imanishi Y, Ito N, Ito N, Tanaka H, Tanaka H, Zhang L, Zhang L, Theodore-Oklota C, Theodore-Oklota C, Mealiffe M, Mealiffe M, Martin J, Martin J, Insogna K. A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH) Endocrine Abstracts 2018 DOI: 10.1530/endoabs.56.oc3.1.
  • ENPP1 Enzyme Replacement Prevents the Osteomalacia and Paradoxical Mineralization in the Enpp1asj/asj mouse model of Autosomal Recessive Hypophosphatemic Rickets Type‐2.Braddock D, Kavanagh D, Li X, Carpenter T, Levine M, Horowitz M. ENPP1 Enzyme Replacement Prevents the Osteomalacia and Paradoxical Mineralization in the Enpp1asj/asj mouse model of Autosomal Recessive Hypophosphatemic Rickets Type‐2. The FASEB Journal 2018, 32: 816.13-816.13. DOI: 10.1096/fasebj.2018.32.1_supplement.816.13.
  • Abstract #512 A Phase 3 Randomized; Placebo-Controlled Study Investigating Burosumab for Adult X-Linked Hypophosphatemia (XLH)De Beur S, De Beur S, Carpenter T, Briot K, Briot K, Imel E, Imel E, Kamenický P, Kamenický P, Ruppe M, Ruppe M, Portale A, Portale A, Weber T, Weber T, Pitukcheewanont P, Pitukcheewanont P, Cheong H, Cheong H, Imanishi Y, Imanishi Y, Ito N, Ito N, Lachmann R, Lachmann R, Tanaka H, Tanaka H, Zhang L, Zhang L, Theodore-Oklota C, Theodore-Oklota C, Mealiffe M, Mealiffe M, San Martin J, San Martin J, Insogna K. Abstract #512 A Phase 3 Randomized; Placebo-Controlled Study Investigating Burosumab for Adult X-Linked Hypophosphatemia (XLH) Endocrine Practice 2018, 24: 112. DOI: 10.1016/s1530-891x(20)47189-7.
  • Abstract #525 Burosumab for X-Linked Hypophosphatemia (XLH): Results from Two Pediatric Phase 2 TrialsPortale A, Imel E, Whyte M, Boot A, Högler W, Linglart A, Padidela R, Hoff W, Gottesman G, Mao M, Skrinar A, San Martin J, Carpenter T. Abstract #525 Burosumab for X-Linked Hypophosphatemia (XLH): Results from Two Pediatric Phase 2 Trials Endocrine Practice 2018, 24: 119-120. DOI: 10.1016/s1530-891x(20)47202-7.
  • Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate AvailabilityImel E, Carpenter T. Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability 2018, 497-524. DOI: 10.1007/978-3-319-73782-9_23.
  • Chapter 83 The Hypocalcemic DisordersGafni R, Gafni R, Insogna K, Carpenter T. Chapter 83 The Hypocalcemic Disorders 2018, 527-547. DOI: 10.1016/b978-0-12-809963-6.00083-3.
  • Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 StudyPortale A, Imel E, Boot A, Högler W, Linglart A, Padidela R, Hoff W, Whyte M, San Martin J, Carpenter T. Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study 2018, 264-264. DOI: 10.1542/peds.141.1_meetingabstract.264.
  • Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 StudyPortale A, Imel E, Boot A, Högler W, Linglart A, Padidela R, Hoff W, Whyte M, San Martin J, Carpenter T. Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study Pediatrics 2018, 141: 264-264. DOI: 10.1542/peds.141.1ma3.264.
  • KRN23 effects on phosphate and vitamin D dysregulation in children <5 years old with X-Linked Hypophosphatemia (XLH)Imel E, Carpenter T, Gottesman G, Martin J, Mao M, Skrinar A, Whyte M. KRN23 effects on phosphate and vitamin D dysregulation in children <5 years old with X-Linked Hypophosphatemia (XLH) Bone Abstracts 2017 DOI: 10.1530/boneabs.6.oc24.
  • A randomized, open-label Phase 2 study of KRN23, an investigational fully human Anti-FGF23 monoclonal antibody, in children with X-linked Hypophosphatemia (XLH)Hogler W, Portale A, Imel E, Boot A, Linglart A, Padidela R, van't H, Whyte M, Mao M, Skrinar A, Martin J, Carpenter T. A randomized, open-label Phase 2 study of KRN23, an investigational fully human Anti-FGF23 monoclonal antibody, in children with X-linked Hypophosphatemia (XLH) Bone Abstracts 2017 DOI: 10.1530/boneabs.6.oc26.
  • Effects of KRN23, a fully human anti-FGF23 monoclonal antibody, on functional outcomes in children with X-linked hypophosphatemia (XLH): results from a randomized, open-label Phase 2 studyImel E, Carpenter T, Linglart A, Boot A, Hogler W, Padidela R, van't H, Portale A, Mao M, Skrinar A, San M, Whyte M. Effects of KRN23, a fully human anti-FGF23 monoclonal antibody, on functional outcomes in children with X-linked hypophosphatemia (XLH): results from a randomized, open-label Phase 2 study Bone Abstracts 2017 DOI: 10.1530/boneabs.6.p063.
  • Single Dose Of Bisphosphonate To Treat Infantile HypercalcemiaPatel N, Carpenter T, Genel M. Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia AACE Clinical Case Reports 2017, 3: e246-e250. DOI: 10.4158/ep161536.cr.
  • Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 studyPadidela R, van't H, Hogler W, Portale A, Imel E, Boot A, Linglart A, Whyte M, Skrinar A, San M, Carpenter T. Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study Endocrine Abstracts 2016 DOI: 10.1530/endoabs.45.oc5.1.
  • Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 studyLinglart A, Carpenter T, Imel E, Boot A, Högler W, Padidela R, Hoff W, Whyte M, Chen C, Skrinar A, Agarwal S, San Martin J, Portale A. Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study Annales D Endocrinologie 2016, 77: 440. DOI: 10.1016/j.ando.2016.07.547.
  • Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label Phase 2 studyImel E, Carpenter T, Boot A, Hogler W, Linglart A, Padidela R, van't H, Whyte M, Agarwal S, Chen C, Skrinar A, Martin J, Portale A. Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label Phase 2 study Bone Abstracts 2016 DOI: 10.1530/boneabs.5.ht6.
  • An Unusual Case of Rickets and How Whole Exome Sequencing Helped to Correct a DiagnosisPeter P, Brownstein C, Yao G, Olear E, Simpson C, Agrawal P, Carpenter T, Insogna K. An Unusual Case of Rickets and How Whole Exome Sequencing Helped to Correct a Diagnosis AACE Clinical Case Reports 2016, 2: ee278-ee283. DOI: 10.4158/ep15944.cr.
  • A Clinician's Guide to X‐Linked HypophosphatemiaCarpenter T, Imel E, Imel E, Holm I, Holm I, de Beur S, de Beur S, Insogna K. A Clinician's Guide to X‐Linked Hypophosphatemia Journal Of Bone And Mineral Research 2015, 30: 394-394. DOI: 10.1002/jbmr.2440.
  • Screening and characterization of vitamin D binding protein variantsFu L, Wong B, Borges C, Williams R, Carpenter T, Cole D. Screening and characterization of vitamin D binding protein variants Clinical Biochemistry 2014, 47: 1149-1150. DOI: 10.1016/j.clinbiochem.2014.06.048.
  • A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemiaCarpenter T, Imel E, Imel E, Ruppe M, Ruppe M, Weber T, Weber T, Klausner M, Klausner M, Wooddell M, Wooddell M, Kawakami T, Kawakami T, Ito T, Ito T, Zhang X, Zhang X, Humphrey J, Humphrey J, Insogna K, Peacock M, Peacock M. A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia Bone Abstracts 2014 DOI: 10.1530/boneabs.3.pp90.
  • Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemiaZhang X, Zhang X, Carpenter T, Imel E, Imel E, Ruppe M, Ruppe M, Weber T, Weber T, Klausner M, Klausner M, Kawakami T, Kawakami T, Ito T, Ito T, Humphrey J, Humphrey J, Insogna K, Peacock M, Peacock M. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia Bone Abstracts 2014 DOI: 10.1530/boneabs.3.pp91.
  • Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate AvailabilityImel E, Carpenter T. Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability 2013, 357-378. DOI: 10.1007/978-1-60761-395-4_21.
  • Chapter 26 Familial Hypophosphatemia and Related DisordersHolm I, Econs M, Carpenter T. Chapter 26 Familial Hypophosphatemia and Related Disorders 2012, 699-726. DOI: 10.1016/b978-0-12-382040-2.10026-7.
  • Hypercalcaemic and hypocalcaemic syndromes in childrenArdeshirpour L, Carpenter T. Hypercalcaemic and hypocalcaemic syndromes in children 2011, 687-700. DOI: 10.1093/med/9780199235292.003.0444.
  • Effect Of Vitamin D Binding Protein (DBP) Genotype On The Development Of Asthma In Young ChildrenNavas-Nazario A, Fangyong L, Northrup V, Weiss P, Cole D, Carpenter T, Bazzy-Asaad A. Effect Of Vitamin D Binding Protein (DBP) Genotype On The Development Of Asthma In Young Children 2011, a1358-a1358. DOI: 10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1358.
  • Chapter 59 The Hypocalcemic Disorders Differential Diagnosis and Therapeutic Use of Vitamin DCarpenter T, Insogna K. Chapter 59 The Hypocalcemic Disorders Differential Diagnosis and Therapeutic Use of Vitamin D 2011, 1091-1106. DOI: 10.1016/b978-0-12-381978-9.10059-9.
  • Differences in 25-Hydroxyvitamin D Levels at Birth in Hispanic and Caucasian Infants Are Not Related to Neonatal Bone Mineral StatusHawthorne K, Hicks P, Rogers S, Carpenter T, Abrams S. Differences in 25-Hydroxyvitamin D Levels at Birth in Hispanic and Caucasian Infants Are Not Related to Neonatal Bone Mineral Status Journal Of The Academy Of Nutrition And Dietetics 2010, 110: a35. DOI: 10.1016/j.jada.2010.06.131.
  • Variations in cord 25‐hydroxyvitamin D levels in Hispanic and Caucasian infants are not related to neonatal bone mineral statusHicks P, Hawthorne K, Rogers S, Carpenter T, Abrams S. Variations in cord 25‐hydroxyvitamin D levels in Hispanic and Caucasian infants are not related to neonatal bone mineral status The FASEB Journal 2010, 24: 325.4-325.4. DOI: 10.1096/fasebj.24.1_supplement.325.4.
  • 25: Functional Analysis of Human Mutations in NAPI-IIC Reveals Important Residues for Surface Expression and Sodium-Phosphate Co-TransportBergwitz C, Jaureguiberry G, Carpenter T, Forman S, Jüppner H. 25: Functional Analysis of Human Mutations in NAPI-IIC Reveals Important Residues for Surface Expression and Sodium-Phosphate Co-Transport American Journal Of Kidney Diseases 2008, 51: b34. DOI: 10.1053/j.ajkd.2008.02.030.
  • CHAPTER 64 The Hypocalcemic Disorders: Differential Diagnosis and Therapeutic Use of Vitamin DCARPENTER T, INSOGNA K. CHAPTER 64 The Hypocalcemic Disorders: Differential Diagnosis and Therapeutic Use of Vitamin D 2005, 1049-1063. DOI: 10.1016/b978-012252687-9/50067-x.
  • Chapter 25 Familial Hypophosphatemia and Related DisordersHolm I, Econs M, Carpenter T. Chapter 25 Familial Hypophosphatemia and Related Disorders 2003, 603-xvi. DOI: 10.1016/b978-012286551-0/50027-0.
  • Evaluation and Treatment of Heritable Forms of RicketsLevine B, Carpenter T. Evaluation and Treatment of Heritable Forms of Rickets The Endocrinologist 1999, 9: 358-365. DOI: 10.1097/00019616-199909000-00006.
  • Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein1Kerstetter J, Kerstetter J, Mitnick M, Mitnick M, Gundberg C, Gundberg C, Caseria D, Caseria D, Ellison A, Ellison A, Carpenter T, Insogna K. Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein1 The Journal Of Clinical Endocrinology & Metabolism 1999, 84: 1052-1055. DOI: 10.1210/jcem.84.3.5552.
  • PediatricsBackeljauw P, Carpenter T. Pediatrics Southern Medical Journal 1997, 90: s105. DOI: 10.1097/00007611-199710001-00219.
  • CARDIOVASCULAR (CV) ABNORMALITIES IN PATIENTS (PTS) WITH X-LINKED HYPOPHOSPHATEMIA (XLH). † 554Nehgme R, Fahey J, Smith C, Carpenter T. CARDIOVASCULAR (CV) ABNORMALITIES IN PATIENTS (PTS) WITH X-LINKED HYPOPHOSPHATEMIA (XLH). † 554 Pediatric Research 1996, 39: 95-95. DOI: 10.1203/00006450-199604001-00575.
  • Effects of phosphorus and 1,25(OH)2D3 on serum osteocalcin in the Hyp mouseGundberg C, Carpenter T. Effects of phosphorus and 1,25(OH)2D3 on serum osteocalcin in the Hyp mouse Bone And Mineral 1992, 17: 132. DOI: 10.1016/0169-6009(92)91868-j.
  • A prospective trial of phosphate and 1,25(OH)2D in symptomatic adults with X-linked hypohosphatemiaCarpenter T, Sullivan W, Sullivan W, Glorieux F, Glorieux F, Travers R, Travers R, Insogna K. A prospective trial of phosphate and 1,25(OH)2D in symptomatic adults with X-linked hypohosphatemia Bone And Mineral 1992, 17: 209. DOI: 10.1016/0169-6009(92)92170-u.
  • CIRCULATING OSTEOCALCIN IN MAGNESIUM DEFICIENCY: RESPONSE TO 1,25(OH)2DCARPENTER T, MITNICK M, JOHNSON P, GUNDBERG C. CIRCULATING OSTEOCALCIN IN MAGNESIUM DEFICIENCY: RESPONSE TO 1,25(OH)2D 1988, 618-619. DOI: 10.1515/9783110846713.618.
  • BONE FRAGILITY, CRANIOSYNOSTOSIS, HYDROCEPHALUS AND OCULAR PROPTOSIS: FURTHER OBSERVATIONS ON A NEWLY RECOGNIZED TYPE OF OSTEOGENESIS IMPERFECTA (OI)Cole D, Carpenter T. BONE FRAGILITY, CRANIOSYNOSTOSIS, HYDROCEPHALUS AND OCULAR PROPTOSIS: FURTHER OBSERVATIONS ON A NEWLY RECOGNIZED TYPE OF OSTEOGENESIS IMPERFECTA (OI) Pediatric Research 1987, 21: 226-226. DOI: 10.1203/00006450-198704010-00360.

Clinical Trials

ConditionsStudy Title
Diseases of the Musculoskeletal SystemTumor-induced Osteomalacia Disease Monitoring Program
Diseases of the Musculoskeletal SystemExamining the Effect of Burosumab on Muscle Function
Diseases of the Musculoskeletal SystemStudy to Assess the Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta
Diseases of the Kidney & Urinary TractThe Impact of Phosphate Metabolism on Healthy Aging